Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company PharmAbcine Inc.
DescriptionBispecific antibody targeting vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2; KDR/Flk-1) and delta-like 4 (DLL4)
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1) ; Delta-like 4 (DLL4)
Mechanism of ActionBispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today